Lisanti Capital Growth LLC Cuts Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)

Lisanti Capital Growth LLC lessened its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 70.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 46,265 shares of the company’s stock after selling 108,445 shares during the quarter. Lisanti Capital Growth LLC owned 0.17% of Castle Biosciences worth $1,233,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in CSTL. R Squared Ltd purchased a new stake in Castle Biosciences during the 4th quarter worth about $42,000. Quest Partners LLC increased its stake in Castle Biosciences by 54.4% in the third quarter. Quest Partners LLC now owns 4,318 shares of the company’s stock valued at $123,000 after purchasing an additional 1,522 shares during the last quarter. US Bancorp DE raised its holdings in Castle Biosciences by 1,889.2% during the third quarter. US Bancorp DE now owns 4,615 shares of the company’s stock worth $132,000 after purchasing an additional 4,383 shares in the last quarter. Point72 DIFC Ltd acquired a new position in Castle Biosciences in the third quarter valued at $140,000. Finally, Assetmark Inc. grew its stake in Castle Biosciences by 16.8% during the 3rd quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock worth $149,000 after buying an additional 748 shares during the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Castle Biosciences Trading Down 3.4 %

Shares of CSTL stock opened at $20.59 on Friday. The firm has a market capitalization of $576.66 million, a PE ratio of 102.96 and a beta of 0.98. Castle Biosciences, Inc. has a 1-year low of $16.97 and a 1-year high of $35.84. The business’s fifty day moving average price is $26.74 and its 200 day moving average price is $29.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64.

Wall Street Analysts Forecast Growth

CSTL has been the subject of a number of research reports. Stephens reaffirmed an “overweight” rating and issued a $41.00 target price on shares of Castle Biosciences in a report on Thursday, January 2nd. Robert W. Baird increased their price target on Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Castle Biosciences currently has an average rating of “Buy” and an average price target of $40.00.

Insider Activity

In other news, insider Derek J. Maetzold sold 9,364 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $28.34, for a total transaction of $265,375.76. Following the sale, the insider now owns 84,762 shares of the company’s stock, valued at $2,402,155.08. The trade was a 9.95 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Daniel Bradbury sold 7,867 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total value of $221,613.39. The disclosure for this sale can be found here. Insiders sold 28,799 shares of company stock worth $824,289 in the last 90 days. 7.20% of the stock is currently owned by corporate insiders.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.